Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials
Abstract
9034 Background: The monoclonal antibody ipilimumab targets cytotoxic T-lymphocyte antigen-4. The most common AEs associated with ipilimumab are irAEs, and both antitumor and irAE responses likely reflect its immune-mediated mechanism of action. In this report, a potential association between disease control (DC) or overall survival (OS) and irAEs in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in 3 Phase II clinical trials was explored. Methods: Across 3 Phase II studies (CA184008, 022, and 007), ipilimumab (10 mg/kg) was given every 3 weeks (Q3W) x 4 (induction); eligible pts could continue to receive ipilimumab Q12W starting at week (wk) 24 (maintenance). In study 022, pts were randomized to 0.3, 3, and 10 mg/kg groups, whereas study 008 was a single-arm trial of ipilimumab 10 mg/kg. In study 007, ipilimumab 10 mg/kg was administered either with placebo or daily prophylactic budesonide. Disease control (CR/PR/SD) was evaluated using modified World Health Organization (mWHO) and immune- related response criteria (Hodi FS, et al. J Clin Oncol 26: 2008 (May 20 suppl; abstr 3008). Association between DC and grade 0/1 vs. grade ≥2 irAEs was examined (studies 007, 008, and 022). Association between OS and irAEs which developed within 12 wks of ipilimumab treatment was also explored using landmark analyses from Day 81 (studies 008 and 022). Results: Across the 3 phase II studies, the rate of DC by mWHO in pts with grade 0/1 irAEs was 20–24% and in pts with grade ≥2 irAEs was 34–43%. The number of pts with DC was higher among those who experienced an irAE compared with those who did not, but DC was not statistically significantly associated with grade 0/1 vs grade ≥2 irAEs. For pts who lived up to Day 81 in studies 008 and 022, median OS (95% CI) from Day 81 was 14.8 mo (10.0–21.7) for any irAE and 8.21 mo (5.29–13.7) for no irAE within 12 weeks; median OS was 13.6 mo (5.78-NR) for any grade ≥2 irAE and 11.3 mo (7.95–15.8) for no grade ≥2 irAE within 12 weeks. Conclusions: DC and survival benefits with ipilimumab are observed among pts that develop an irAE and among pts that do not develop an irAE. Thus, pts who do not experience an irAE may still demonstrate clinical benefit with ipilimumab. [Table: see text]
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In that aggregate analysis, OS did not differ by grade in patients who experienced IRAEs.
“however did not differ by grade in patients who experienced IRAEs.”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [48]
In that aggregate analysis, there was no statistically significant difference in DCR between patients with grade 1 vs grade ≥ 2 IRAEs (20-24% vs 34%).
“there was no statistically significant difference in DCR between patients with grade 1 vs grade ≥ 2 IRAEs (20–24% vs 34%).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [48]
In an aggregate analysis of 3 phase II studies in metastatic melanoma patients treated with ipilimumab, DCR was higher in patients who experienced any IRAEs compared to those who did not (rates not specified).
“Although DCR was higher in patients who experienced any IRAEs compared to those who did not experience them (rates not specified)”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [48]
In that aggregate analysis, OS was improved in patients who experienced IRAEs compared to those who did not (14.8 vs 8.2 months).
“OS was also improved in patients who experienced IRAEs compared to those who did not experience them (14.8 vs 8.2 months)”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [48]
Cited by
Sorted by citations
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415 · see citing works
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Das, S., & Johnson, D. B. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0805-8 · Cited by 1,145 · see citing works
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,090 · see citing works
Wilgenhof, S., Corthals, J., Heirman, C., van Baren, N., Lucas, S., Kvistborg, P., Thielemans, K., & Neyns, B. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4121 · Cited by 312 · see citing works
“Such correlation has been reported previously for ipilimumab monotherapy but did not reach significance.(42) Resembling previous observations on patients treated with corticosteroids to control immune-related AEs related to ipilimumab, we suspect no detrimental effect from our observations.”
ResultCombination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Vafaei, S., Zekiy, A. O., Khanamir, R. A., Zaman, B. A., Ghayourvahdat, A., Azimizonuzi, H., & Zamani, M. (2022) · Cancer Cell International · doi:10.1186/s12935-021-02407-8 · Cited by 278 · see citing works
“During the last decade, some clinical trials have indicated that monotherapy with ipilimumab (10 mg/ kg) in patients with advanced melanoma could result in improved OS rate [74], and a durable objective response [75].”
BackgroundDevelopment of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
Hoos, A., Ibrahim, R. A., Korman, A. J., Abdallah, K. A., Berman, D., Shahabi, V., Chin, K. M., Canetta, R. M., & Humphrey, R. W. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.015 · Cited by 242 · see citing works
Self-citationTarhini, A. A. (2013) · Scientifica · doi:10.1155/2013/857519 · Cited by 235 · see citing works
Kaehler, K. C., Piel, S., Livingstone, E., Schilling, B., Hauschild, A., & Schadendorf, D. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.003 · Cited by 170 · see citing works
Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer
Graziani, G., Tentori, L., & Navarra, P. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.09.002 · Cited by 164 · see citing works
Ascierto, P. A., Simeone, E., Chiarion‐Sileni, V., Pigozzo, J., Maio, M., Altomonte, M., Vecchio, M. D., Guardo, L. D., Marchetti, P., Ridolfi, R., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-116 · Cited by 163 · see citing works
Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors
Tarhini, A. A., Lo, E., & Minor, D. R. (2010) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0865 · Cited by 159 · see citing works
Clinical assessment of immune-related adverse events
Sosa, A. E., Cadena, E. L., Olivé, C. S., Karachaliou, N., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918764628 · Cited by 135 · see citing works
Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanoma
Kähler, K. C., & Hauschild, A. (2010) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2010.07568.x · Cited by 108 · see citing works
Ipilimumab in the treatment of metastatic melanoma: management of adverse events
Scarpati, G. D. V., Fusciello, C., Perri, F., Sabbatino, F., Carlomagno, C., Pepe, S., & Ferrone, S. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s57335 · Cited by 106 · see citing works
“12 However, recently, some evidence has indicated that ipilimumab-induced irAEs may be associated with clinical benefit, 13,14 even in the adjuvant setting in resected high-risk stage IIIC/IV melanoma patients.”
Lisi, L., Lacal, P. M., Martire, M., Navarra, P., & Graziani, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105997 · Cited by 105 · see citing works
Vogt-Koyanagi-Harada-like Syndrome After CTLA-4 Inhibition With Ipilimumab for Metastatic Melanoma
Crosson, J. N., Laird, P. W., Debiec, M. R., Bergstrom, C. S., Lawson, D. H., & Yeh, S. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000066 · Cited by 91 · see citing works
Lankes, K., Hundorfean, G., Harrer, T., Pommer, A. J., Agaimy, A., Angelovska, I., Tajmir-Riahi, A., Göhl, J., Schuler, G., Neurath, M. F., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1128611 · Cited by 85 · see citing works
CTLA-4 blockade: therapeutic potential in cancer treatments
Tarhini, A. A. (2010) · OncoTargets and Therapy · doi:10.2147/ott.s4833 · Cited by 84 · see citing works
Giacomo, A. M. D., Danielli, R., Calabrò, L., Bertocci, E., Nannicini, C., Giannarelli, D., Balestrazzi, A., Vigni, F., Riversi, V., Miracco, C., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0958-2 · Cited by 81 · see citing works
“Evidence suggests that the occurrence of irAEs in patients may be associated with tumor regression and prolonged time to relapse [13], however, patients who have not experienced an irAE have also demonstrated DC upon ipilimumab therapy [14, 25].”
BackgroundNg, K. Y. Y., Tan, S. H., Tan, J. J. E., Tay, D. S. H., Lee, A. W. X., Ang, A. J. S., Wong, L. W. J., Choo, S. P., Tai, D. W.-M., & Lee, J. J. X. (2021) · Liver Cancer · doi:10.1159/000518619 · Cited by 75 · see citing works
Gelao, L., Criscitiello, C., Espósito, A., Goldhirsch, A., & Curigliano, G. (2014) · Toxins · doi:10.3390/toxins6030914 · Cited by 68 · see citing works
“In a trial in which 56 Stage IV melanoma patients were treated with ipilimumab and a peptide vaccine, 36% of patients who had a severe irAE achieved a clinical response, whereas only 5% of patients without an irAE showed a response [88].”
Shafqat, H., Gourdin, T. S., & Sion, A. M. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.07.003 · Cited by 66 · see citing works
Cortellini, A., Buti, S., Agostinelli, V., & Bersanelli, M. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.10.003 · Cited by 62 · see citing works
New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors
Ciccarese, C., Alfieri, S., Santoni, M., Santini, D., Brunelli, M., Bergamini, C., Licitra, L. F., Montironi, R., Tortora, G., & Massari, F. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1120287 · Cited by 62 · see citing works
Berman, D., Korman, A. J., Peck, R., Feltquate, D., Lönberg, N., & Canetta, R. M. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.017 · Cited by 62 · see citing works
Damuzzo, V., Solito, S., Pinton, L., Carrozzo, E., Valpione, S., Pigozzo, J., Arboretti, R., Chiarion‐Sileni, V., & Mandruzzato, S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1249559 · Cited by 59 · see citing works
“irADR and clinical benefit was not confirmed by large perspective studies.(47,48) Our results indicate that the development of”
ResultSerious haematological toxicity during and after ipilimumab treatment: a case series
Simeone, E., Grimaldi, A. M., Esposito, A., Curvietto, M., Palla, M., Paone, M., Mozzillo, N., & Ascierto, P. A. (2014) · Journal of Medical Case Reports · doi:10.1186/1752-1947-8-240 · Cited by 56 · see citing works
“Early ipilimumab trials suggested an association between development of immune-related adverse events and clinical response [12].”
BackgroundCombination of targeted therapy and immunotherapy in melanoma
Blank, C. U., Hooijkaas, A. I., Haanen, J. B. A. G., & Schumacher, T. N. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1079-2 · Cited by 41 · see citing works
Assi, H. I., & Wilson, K. S. (2013) · Current Oncology · doi:10.3747/co.20.1265 · Cited by 41 · see citing works
Specenier, P. M. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1211936 · Cited by 37 · see citing works
FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls
Cho, S. Y., Huff, D. T., Jeraj, R., & Albertini, M. (2020) · Seminars in nuclear medicine · doi:10.1053/j.semnuclmed.2020.06.001 · Cited by 31 · see citing works
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
Hu, W., Wang, G., Wang, Y., Riese, M. J., & You, M. (2020) · iScience · doi:10.1016/j.isci.2020.101580 · Cited by 35 · see citing works
“Additionally, the overall survival (OS) of patients who experienced irAEs was also improved in patients with grade 2 or greater irAEs compared with grade 0 or 1 irAEs (14.8 versus 8.2 months) (Lutzky et al., 2009).”
BackgroundInfluentialResponses to immune checkpoint inhibitors in nonagenarians
Johnpulle, R. A. N., Conry, R. M., Sosman, J. A., Puzanov, I. J., & Johnson, D. B. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1234572 · Cited by 27 · see citing works
Targeting Cytotoxic T-Lymphocyte Antigen 4 in Immunotherapies for Melanoma and Other Cancers
Page, D. B., Yuan, J. D., & Wolchok, J. D. (2010) · Immunotherapy · doi:10.2217/imt.10.21 · Cited by 23 · see citing works
Self-citationWiater, K., Świtaj, T., Mackiewicz, J., Kalinka‐Warzocha, E., Wojtukiewicz, M. Z., Szambora, P., Falkowski, S., Rogowski, W., Mackiewicz, A. A., & Rutkowski, P. L. (2013) · Współczesna Onkologia · doi:10.5114/wo.2013.35785 · Cited by 20 · see citing works
Managing Immune-Related Adverse Events to Ipilimumab: A Nurse's Guide
Rubin, K. M. (2012) · Clinical journal of oncology nursing · doi:10.1188/12.cjon.e69-e75 · Cited by 20 · see citing works
Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers
Ettl, T., Grube, M., Schulz, D., & Bauer, R. J. (2022) · Cancers · doi:10.3390/cancers14204985 · Cited by 19 · see citing works
“Clinical trials have shown that monotherapy with ipilimumab (10 mg/kg) can lead to improved OS rates [70] and durable objective response in patients with advanced melanoma [71].”
BackgroundMandalà, M., Larkin, J., Ascierto, P. A., Vecchio, M. D., Gogas, H. J., Cowey, C. L., Arance, A. M., Dalle, S., Schenker, M., Grob, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003188 · Cited by 17 · see citing works
Self-citationNew Therapeutic Options in the Medical Management of Advanced Melanoma
Lutzky, J. (2010) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2010.10.006 · Cited by 17 · see citing works
Self-citationFranken, M. G., Leeneman, B., Jochems, A., et al. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000628 · Cited by 17 · see citing works
Agarwala, S. S., & O'Day, S. J. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.06.001 · Cited by 16 · see citing works
Self-citationMonoclonal Antibodies to CTLA-4 with Focus on Ipilimumab
Graziani, G., Lisi, L., Tentori, L., & Navarra, P. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_10 · Cited by 15 · see citing works
Holstead, R. G., Kartolo, B., Hopman, W. M., & Baetz, T. D. (2021) · Melanoma Research · doi:10.1097/cmr.0000000000000736 · Cited by 14 · see citing works
Toxicity of checkpoint inhibitors.
Schmerling, R. A. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2014.08.03 · Cited by 12 · see citing works
“Although, there is data suggesting that toxicity is directly related to its efficacy, this has not been widely accepted (36,37).”
BackgroundGoldman, C., Tchack, J., Robinson, E. M., Han, S. W., Moran, U., Polsky, D., Berman, R. S., Shapiro, R. L., Ott, P. A., Osman, I., et al. (2017) · Oncology · doi:10.1159/000475715 · Cited by 8 · see citing works
Severe colitis while responding to ipilimumab in metastatic melanoma
Slingerland, M., Nortier, J. W. R., Veenendaal, R. A., & Kapiteijn, E. (2012) · Acta Oncologica · doi:10.3109/0284186x.2012.682630 · Cited by 7 · see citing works
Macroangiopathy is a positive predictive factor for response to immunotherapy
Deike‐Hofmann, K., Gutzweiler, L., Reuter, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46189-6 · Cited by 8 · see citing works
Colitis secundaria a ipilimumab: un nuevo reto para el gastroenterólogo
Mesonero, F., López–Sanromán, A., Madariaga, A., & Soria, A. (2015) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2015.06.005 · Cited by 6 · see citing works
Checkpoint inhibitors in the treatment of cutaneous malignant melanoma.
Lutzky, J. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2014.05.13 · Cited by 6 · see citing works
“Retrospective analyses of large studies have suggested better clinical outcomes in patients treated with anti-CTLA-4 antibodies who experienced irAEs; this effect appeared to be more pronounced in patients who had more severe irAEs (46-48).”
ResultSelf-citationSpecenier, P. M. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.132 · Cited by 6 · see citing works
Sheng, J., Nayeni, M., & Malvankar‐Mehta, M. S. (2024) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552241243042 · Cited by 3 · see citing works
“In the current systematic review, median OS was lowest in the cohort study conducted by Kobayashi et al. 15 Although statistical signi fi cance was not calculated, there was an improvement in median OS among patients with any grade irAEs compared to those without irAEs in the two clinical trials analyzed by Lutzky et a…”
Ipilimumab-induced colitis: A new challenge for gastroenterologists
Mesonero, F., López–Sanromán, A., Madariaga, A., & Soria, A. (2016) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2016.02.016 · Cited by 3 · see citing works
Tokudome, T. (2016) · Springer eBooks · doi:10.1007/978-4-431-55031-0_18 · Cited by 2 · see citing works
Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab
Graziani, G., Tentori, L., & Navarra, P. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1300-4_10 · Cited by 2 · see citing works
“Several trials have reported a possible correlation between grade 3 and 4 irAEs with the clinical efficacy of ipilimumab [93, 94], suggesting that tumour regression is associated with the development of autoimmunity.”
BackgroundZhang, J., He, X., Zhang, Y., Qian, X., Song, Y., Shilong, Z., Li, Z., Wang, Z., Lu, B., cai, Q., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014290 · Cited by 1 · see citing works
“11 Although the exact mechanism remains unclear, the hyperactivation of the immune system associated with irAEs may contribute to enhanced tumor control.”
ANTICUERPOS MONOCLONALES EN EL TRATAMIENTO DEL CÁNCER. TERAPIA DIRIGIDA PARA TUMORES SÓLIDOS
Fuenmayor, J., Hoyos, R. G., & Montaño, R. F. (2013) · Redalyc (Universidad Autónoma del Estado de México)
Hypophysitis als Folge einer Ipilimumab-Therapie bei metastasiertem Melanom
Dietrich, K., Rübsam, K., Schneider, H. J., et al. (2013) · Fortschritte der praktischen Dermatologie und Venerologie · doi:10.1007/978-3-642-24767-5_85
- Authors
- Lutzky, J., Wolchok, J., Hamid, O., Lebbe, C., Pehamberger, H., Linette, G., de Pril, V., Ibrahim, R., Hoos, A., & O'Day, S.
- Affiliations
- University of Vienna (AT)
- Mt Sinai Comprehensive Cancer Center, Miami Beach, FL; Memorial Sloan-Kettering Cancer Center, New York, NY; The Angeles Clinic and Research Institute, Santa Monica, CA; Saint-Louis Hospital, Paris, France; University of Vienna, Vienna, Austria; Washington University School of Medicine, St. Louis, MO; Bristol-Myers Squibb, Braine l'Alleud, Belgium; Bristol-Myers Squibb, Wallingford, CT
- Venue
- Journal of Clinical Oncology
- Published
- 2009-05-20
- Volume
- 27
- Issue
- 15_suppl
- Pages
- 9034-9034
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2280151081
- Cited by
- 58
- References
- 0
- Citations by year
- 2026: 1 · 2024: 1 · 2022: 3 · 2021: 4 · 2020: 2 · 2019: 4 · 2018: 3 · 2017: 1 · 2016: 8 · 2015: 3 · 2014: 7 · 2013: 6 · 2012: 4
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune-related adverse events, ipilimumab, advanced melanoma, CTLA-4 blockade, disease control, overall survival, immune checkpoint inhibitors, immune-related response criteria, immune-related toxicity, maintenance therapy, dose escalation, landmark analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
